Alane Izu to Vaccination
This is a "connection" page, showing publications Alane Izu has written about Vaccination.
Connection Strength
0,694
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,175
-
Hospitalization for Culture-confirmed Pulmonary Tuberculosis in the Era of Childhood Pneumococcal Conjugate Vaccine Immunization. Pediatr Infect Dis J. 2017 01; 36(1):e14-e21.
Score: 0,117
-
Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa. Clin Infect Dis. 2016 May 01; 62 Suppl 2:S188-95.
Score: 0,112
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19. Nat Immunol. 2023 07; 24(7):1161-1172.
Score: 0,046
-
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005). Vaccine. 2023 05 26; 41(23):3486-3492.
Score: 0,045
-
Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana. J Infect. 2023 06; 86(6):603-606.
Score: 0,045
-
Methodology for a correlate of protection for group B Streptococcus: Report from the Bill & Melinda Gates Foundation workshop held on 10 and 11 February 2021. Vaccine. 2022 07 30; 40(32):4283-4291.
Score: 0,043
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0,040
-
Immunization in pregnancy safety surveillance in low and middle-income countries- field performance and validation of novel case definitions. Vaccine. 2019 05 16; 37(22):2967-2974.
Score: 0,034
-
Temporal Changes in Invasive Group B Streptococcus Serotypes: Implications for Vaccine Development. PLoS One. 2016; 11(12):e0169101.
Score: 0,029
-
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA. 1999 Jul 28; 282(4):331-40.
Score: 0,009